Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in Adult Patients with β- Thalassemia Major: A Real-Life Study.
Adult
Antiviral Agents
/ adverse effects
Benzimidazoles
Drug Therapy, Combination
Fluorenes
/ adverse effects
Genotype
Hepatitis C, Chronic
/ diagnosis
Humans
Retrospective Studies
Sofosbuvir
/ adverse effects
Thalassemia
/ chemically induced
Treatment Outcome
Uridine Monophosphate
/ adverse effects
beta-Thalassemia
/ complications
HCV
blood diseases
chronic liver disease
cirrhosis
sofosbuvir/ledipasvir
β- Thalassemia major
Journal
Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
09
2020
revised:
06
12
2020
accepted:
14
12
2020
pubmed:
4
2
2021
medline:
25
5
2022
entrez:
3
2
2021
Statut:
ppublish
Résumé
Patients with thalassemia have a lifelong need for blood transfusion, which makes them more risky to hepatitis C virus (HCV). Iron overload and chronic HCV are considered risk factors for patients with thalassemia to develop liver insults. The aim of the present study is to investigate the safety and efficacy of sofosbuvir/ledipasvir in the treatment of chronic HCV infection in Egyptian adult patients with β- thalassemia major. A retrospective study included 53 patients with β-thalassemia major with chronic HCV treated with sofosbuvir (400 mg) and ledipasvir (90 mg) as a single pill fixed-dose combination once daily for 12 weeks. The effectiveness of the treatment was assessed by the sustained virologic response (SVR) at 12 weeks after the end of the treatment. SVR was achieved in 96.23% of patients. 47.17% of patients had minor side effects. There was a significant reduction in ALT, AST, and serum ferritin 12 weeks post-therapy. There was an insignificant change in hemoglobin level or blood transfusion requirement 12 weeks posttherapy. There was no change in iron chelators doses throughout the study period. Sofosbuvir/ledipasvir regimen seems to be safe and highly effective in the treatment of chronic HCV in patients with β-thalassemia major.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Patients with thalassemia have a lifelong need for blood transfusion, which makes them more risky to hepatitis C virus (HCV). Iron overload and chronic HCV are considered risk factors for patients with thalassemia to develop liver insults. The aim of the present study is to investigate the safety and efficacy of sofosbuvir/ledipasvir in the treatment of chronic HCV infection in Egyptian adult patients with β- thalassemia major.
METHODS
METHODS
A retrospective study included 53 patients with β-thalassemia major with chronic HCV treated with sofosbuvir (400 mg) and ledipasvir (90 mg) as a single pill fixed-dose combination once daily for 12 weeks. The effectiveness of the treatment was assessed by the sustained virologic response (SVR) at 12 weeks after the end of the treatment.
RESULTS
RESULTS
SVR was achieved in 96.23% of patients. 47.17% of patients had minor side effects. There was a significant reduction in ALT, AST, and serum ferritin 12 weeks post-therapy. There was an insignificant change in hemoglobin level or blood transfusion requirement 12 weeks posttherapy. There was no change in iron chelators doses throughout the study period.
CONCLUSION
CONCLUSIONS
Sofosbuvir/ledipasvir regimen seems to be safe and highly effective in the treatment of chronic HCV in patients with β-thalassemia major.
Identifiants
pubmed: 33530921
pii: EMIDDT-EPUB-113871
doi: 10.2174/1871530321666210202150538
doi:
Substances chimiques
Antiviral Agents
0
Benzimidazoles
0
Fluorenes
0
ledipasvir
013TE6E4WV
Uridine Monophosphate
E2OU15WN0N
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-296Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.